NASDAQ · CMPS
COMPASS Pathways plc
$11.88-$0.31 (-2.54%)
COMPASS Pathways plc’s quoted price sits in the upper half of its reported 52-week range, 25.14% below the high.
Loading market information…
NASDAQ · NNNN · USD
Stock price, earnings
Quote as of Oct 30, 2026, 01:36 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Anbio Biotechnology Class A Ordinary Shares’s quoted price sits in the lower half of its reported 52-week range, 91.67% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Anbio Biotechnology Class A Ordinary Shares’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Anbio Biotechnology, established in 2021 and based in Frankfurt am Main, Germany, operates as a global supplier of in vitro diagnostics (IVD) products. The company's international footprint covers regions such as the European Union, Asia Pacific, North America, South America, and Africa. Their product range features various diagnostic solutions, including rapid antigen tests for SARS-CoV-2 (both individual and combined with influenza A/B). Anbio also develops and manufactures products leveraging advanced technologies like lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification (LAMP), chemiluminescence immunoassay (CLIA), and reverse-transcription polymerase chain reaction (RT-PCR). These offerings cater to a wide array of markets, including over-the-counter sales, point-of-care testing, and traditional laboratory settings.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:41 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$11.88-$0.31 (-2.54%)
COMPASS Pathways plc’s quoted price sits in the upper half of its reported 52-week range, 25.14% below the high.
$27.00$0.00 (0.0%)
KalVista Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$24.99+$0.01 (+0.04%)
Avanos Medical, Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.96% below the high.
$52.30+$0.85 (+1.65%)
Rigel Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.71% below the high.
$5.25$0.00 (0.0%)
Talkspace, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$12.22-$0.13 (-1.05%)
AngioDynamics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 24.98% below the high.
$2.38-$0.04 (-1.45%)
Community Health Systems, Inc.’s quoted price sits in the lower half of its reported 52-week range, 43.45% below the high.
$10.47-$0.23 (-2.1%)
ClearPoint Neuro, Inc.’s quoted price sits in the lower half of its reported 52-week range, 57.72% below the high.
